3E Bioventures Capital — 2017 Investments

1 investments dated 2017 · listed companies and verified rows first · show all

OncoImmuneoncoimmune.comJan 2017

First-in-class biologic drug targeting the CD24-Siglec innate immunity signaling pathway.

BiotechRockville, US

Pan Zheng(Executive Officer)Kun-Liang Guan(Director)Miao Hong(Director)Martin Devenport(Executive Officer)Yang Liu(Executive Officer, Director)Gary Fanger(Director)

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.